ESR1 and cancer: As reviewed by Kapinova et al. [101], ER-negative breast cancers that are not responsive to selective estrogen receptor modulators such as tamoxifen could be sensitized by phytochemicals and improve the therapeutic outcome when used with other anti-cancer agents.